These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 16607109

  • 1. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S, Grady D, Quan J, Vittinghoff E, Wallace R, Hanes V, Ensrud K.
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [Abstract] [Full Text] [Related]

  • 2. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
    Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D.
    Obstet Gynecol; 2005 Apr; 105(4):779-87. PubMed ID: 15802405
    [Abstract] [Full Text] [Related]

  • 3. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women.
    Huang A, Yaffe K, Vittinghoff E, Kuppermann M, Addis I, Hanes V, Quan J, Grady D.
    Am J Obstet Gynecol; 2008 Mar; 198(3):265.e1-7. PubMed ID: 18313446
    [Abstract] [Full Text] [Related]

  • 4. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women.
    Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, Martin KA.
    Menopause; 2006 Mar; 13(3):411-22. PubMed ID: 16735938
    [Abstract] [Full Text] [Related]

  • 5. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S, Ylikorkala O, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 Mar; 42 Suppl 2():376-87. PubMed ID: 9397385
    [Abstract] [Full Text] [Related]

  • 6. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA, Schaefers M, Uddin A, Utian WH.
    Menopause; 2009 Mar; 16(5):877-82. PubMed ID: 19458560
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ, Sun LZ, Lin JF, Yang X, Zhang LJ, Qiao J, Wang ZH, Xu YX, Xiong ZA, Lin SQ.
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
    Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC.
    Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
    [Abstract] [Full Text] [Related]

  • 10. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G, Dvorak V, Genazzani AR, Hamann B, Heikkinen J, Mueck AO, Suzin J, Kawakami FT, Ferreira A, Sun D, Arguinzoniz M.
    Maturitas; 2007 Jun 20; 57(2):171-81. PubMed ID: 17317046
    [Abstract] [Full Text] [Related]

  • 11. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
    Grady D, Vittinghoff E, Lin F, Hanes V, Ensrud K, Habel LA, Wallace R, Macer J, Cummings SR, Shepherd J.
    Menopause; 2007 Jun 20; 14(3 Pt 1):391-6. PubMed ID: 17224859
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.
    Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E, Grady D.
    Obstet Gynecol; 2004 Sep 20; 104(3):443-51. PubMed ID: 15339752
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.
    Am J Obstet Gynecol; 2004 Dec 20; 191(6):1979-88. PubMed ID: 15592280
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA, ESTRASORB Study Group.
    Menopause; 2006 Dec 20; 13(2):222-31. PubMed ID: 16645536
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.